Polyglutamine toxicity in non-neuronal cells

Cell Research

Volumn 20, Issue 4, 2010, Pages 400-407

  Bradford, Jennifer W ^a   Li, Shihua ^a   Li, Xiao Jiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Glia; Huntington's disease; Misfolding; Neurodegeneration; Polyglutamine

Indexed keywords

PEPTIDE; POLYGLUTAMINE;

CYTOLOGY; DEMYELINATING DISEASE; GENETICS; GLIA; HUMAN; HUNTINGTON CHOREA; METABOLISM; MUSCLE ATROPHY; MYOCLONUS EPILEPSY; REVIEW; SPINOCEREBELLAR DEGENERATION;

HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; MUSCULAR DISORDERS, ATROPHIC; MYOCLONIC EPILEPSIES, PROGRESSIVE; NEUROGLIA; PEPTIDES; SPINOCEREBELLAR ATAXIAS;

EID: 77950547307     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.32     Document Type: Review

References (88)

1. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000; 23:217-247.
2. Li SH, Li XJ. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegeneration 2006; 1:19.
3. Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009; 58:318-328.
4. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009; 8:765-774.
5. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-983.
6. Kremer B, Goldberg P, Andrew SE, et al. World wide distribution of the Huntington disease (HD) mutation: The sensitivity and specificity of CAG repeat length assessment. New Engl J Med 1994; 330:1401-1406.
7. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44:559-577.
8. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000; 26:300-306.
9. Harjes P, Wanker E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 2003; 28:425-433. (Pubitemid 36976745)
10. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20:146-154. (Pubitemid 38230029)
11. Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001; 98:12784-12789. (Pubitemid 33020022)
12. Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci 2002; 22:4842-4849. (Pubitemid 37465599)
13. Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 2002; 22:7862-7872.
14. Lunkes A, Lindenberg KS, Ben-Haïem L, et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 2002; 10:259-269. (Pubitemid 35007341)
15. Qin ZH, Gu ZL. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin 2004; 25:1243-1249. (Pubitemid 39361794)
16. DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995; 14:1075-1081.
17. Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995; 14:1065-1074.
18. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277:1990-1993. (Pubitemid 27449140)
19. Beal MF, Ferrante R. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev 2004; 5:373-384. (Pubitemid 38568498)
20. Soong BW, Paulson HL. Spinocerebellar ataxias: an update. Curr Opin Neurol 2007; 20:438-446.
21. Chung MY, Ranum LP, Duvick LA, Servadio A, Zoghbi HY, Orr HT. Evidence for a mechanism predisposing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. Nat Genet 1993; 5:254-258. (Pubitemid 23330388)
22. Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14:285-291. (Pubitemid 126449762)
23. Warrick JM, Morabito LM, Bilen J, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin- associated mechanism. Mol Cell 2005; 18:37-48. (Pubitemid 40444646)
24. Kordasiewicz HB, Thompson RM, Clark HB, Gomez CM. C-termini of P/Q-type Ca21 channel a1A subunits translocate to nuclei and promote polyglutamine- mediated toxicity. Hum Mol Genet 2006; 15:1587-1599.
25. Stevanin G, Giunti P, Belal GD, et al. De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Hum Mol Genet 1998; 7:1809-1813. (Pubitemid 28464157)
26. La Spada AR, Fu YH, Sopher BL, et al. Polyglutamineexpanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 2001; 31:913-927. (Pubitemid 32925279)
27. Friedman MJ, Shah AG, Fang ZH, et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 2007; 10:1519-1528.
28. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989; 112:209-232. (Pubitemid 19056483)
29. Suzuki K, Katsuno M, Banno H, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008; 131:229-239.
30. Tanaka F, Reeves MF, Ito Y, et al. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level. Am J Hum Genet 1999; 65:966-973. (Pubitemid 30462953)
31. Soukup GR, Sperfeld AD, Uttner I, et al. Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients. J Neurol 2009; 256:1869-1875.
32. Sperfeld AD, Karitzky J, Brummer D, et al. X-linked bulbospinal neuronopathy. Arch Neurol 2002; 59:1921-1926.
33. Yamada M, Shimohata M, Sato T, Tsuji S, Takahashi H. Polyglutamine disease: recent advances in the neuropathology of dentatorubralpallidoluysian atrophy. Neuropathology 2006; 26:346-351. (Pubitemid 44086839)
34. Yu J, Ying M, Zhuang Y, et al. C-terminal deletion of the atrophin-1 protein results in growth retardation but not neurodegeneration in mice. Dev Dyn 2009; 238:2471-2478.
35. Schilling G, Wood JD, Duan K, et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 1999; 24:275-286. (Pubitemid 29466165)
36. Lobsiger C, Cleveland D. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007; 10:1355-1360. (Pubitemid 350014678)
37. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171:1001-1012. (Pubitemid 41815832)
38. Chou SY, Weng JY, Lai HL, et al. Expanded-polyglutamine Huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008; 28:3277-3290.
39. Singhrao SK, Thomas P, Wood DJ, et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 1998; 150:213-222. (Pubitemid 28231952)
40. Rosas HD, Lee SY, Bender A, et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage 2009; 49:2995-3004.
41. Wang CE, Tydlacka S, Orr AL, et al. Accumulation of Nterminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet 2008; 17:2738-2751.
42. Tydlacka S, Wang CE, Wang X, Li S, Li XJ. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008; 28:13285-13295.
43. Maragakis N, Rothstein J. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006; 2:679-689. (Pubitemid 44782682)
44. Lievens JC, Woodman B, Mahal A, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001; 8:807-821. (Pubitemid 33055597)
45. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamateglutamine cycling: downstream effects of the Huntington mutation. Brain 2002; 125:1908-1922.
46. Arzberger T, Krampfl K, Leimgruber S, Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J Neuropathol Exp Neurol 1997; 56:440-454. (Pubitemid 27465027)
47. Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008; 33:232-237.
48. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005; 14:713-724. (Pubitemid 40309596)
49. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106:22480-22485.
50. Custer SK, Garden GA, Gill N, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 2006; 10:1302-1311. (Pubitemid 44454272)
51. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. TINS 1997; 20:570-577. (Pubitemid 27508969)
52. Brenner M, Messing A. GFAP transgenic mice. Methods 1996; 10:351-364. (Pubitemid 26391934)
53. Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11: 251-253. (Pubitemid 351311795)
54. Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60:161-172. (Pubitemid 32172419)
55. Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 2003; 23:2193-2202. (Pubitemid 36368907)
56. Tai YF, Pavese N, Gerhard A, et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72:148-151. (Pubitemid 46389550)
57. Kim S, de Vellis J. Microglia in health and disease. J Neurosci Res 2005; 81:302-313. (Pubitemid 41359284)
58. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the subatantia nigra of Parkinson's and Alzheimer's disease brain. Neurology 1988; 35:1285-1291.
59. Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non- CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009; 30:e8025.
60. Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions associated with Huntington's disease at death: a case-control study. Arch Neurol 1988; 45:878-880.
61. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007; 25:297-308. (Pubitemid 46127844)
62. Pattison J, Robbins J. Protein misfolding and cardiac disease: establishing cause and effect. Autophagy 2008; 4:821-823.
63. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 2008; 117:2743-2751. (Pubitemid 351770455)
64. Podolsky S, Leopold N, Sax D. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; 1:1356-1358.
65. Farrer LA. Diabetes mellitus in Huntington's disease. Clin Genet 1985; 27:62-67.
66. Podolsky S, Leopold N. Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 1977; 23:55-63.
67. Andreassen OA, Dedeoglu A, Stanojevic V, et al. Huntington's disease of the endrocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 2002; 11:410-424. (Pubitemid 36269126)
68. Bjorkqvist M, Fex M, Renström E, et al. The R6/2 transgenic mouse models of Huntington's disease develops diabetes due to deficient ?-cell mass and exocytosis. Hum Mol Genet 2005; 14:565-574. (Pubitemid 40309582)
69. Josefsen K, Nielsen MD, Jørgensen KH, et al. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J Neuroendocrinol 2008; 20:165-172. (Pubitemid 351147003)
70. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001; 8:479-491. (Pubitemid 32566138)
71. Phan J, Hickey M, Zhang P, Chesselet MF, Reue K. Adiposed tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 2009; 18:1006-1016.
72. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48:800-804.
73. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum Mol Genet 2001; 10:145-152. (Pubitemid 32098124)
74. Li SH, Yu ZX, Li CL, et al. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J Neurosci 2003; 23:6956-6964.
75. Henry BA, Clarke IJ. Adipose tissue hormones and the regulation of food intake. J Neuroendocrinol 2008; 20:842-849. (Pubitemid 351858738)
76. Djoussé L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington's disease. Neurology 2002; 59:1325-1330. (Pubitemid 35285981)
77. Lee ST, Chu K, Jung KH, et al. Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 2009; 66:671-681.
78. Sathasivam K, Hobbs C, Turmaine M, et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8:813-822. (Pubitemid 29189048)
79. Ribchester RR, Thomson D, Wood NI, et al. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 2004; 20:3092-3114. (Pubitemid 40007304)
80. Strand A, Aragaki A, Shaw D, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 2005; 14:1863-1876. (Pubitemid 41418057)
81. Carter RJ, Lione LA, Humby T, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999; 19:3248-3257. (Pubitemid 29174016)
82. Luthi-Carter R, Hanson S, Strand A, et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002; 11:1911-1926.
83. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006; 4:349-362. (Pubitemid 44645069)
84. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC- 1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009; 18:3048-3065.
85. Masuda N, Peng Q, Li Q, et al. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 2008; 30:293-302.
86. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20:4389-4397. (Pubitemid 30396603)
87. Martin B, Golden E, Keselman A, et al. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol 2008; 23:237-250.
88. Miller BR, Dorner JL, Shou M, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008; 153:329-337.